Finance

Lists
CHEOY:OTCMKTS
Cochlear Ord ADR
USD 45,04
+0,46%
(+0,20) 1D
13 Okt., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CHEOY...
Open
USD 43,38
High
USD 46,89
Low
USD 43,38
Mkt. cap
8,45 mjd
Avg. vol.
23,46 k
Volume
46,78 k
52-wk high
USD 98,49
52-wk low
USD 31,82
Beta
0,68
Shares outstanding
130,80 m
No. of employees
5 k
Open
USD 43,38
High
USD 46,89
Low
USD 43,38
Mkt. cap
8,45 mjd
Avg. vol.
23,46 k
Volume
46,78 k
52-wk high
USD 98,49
52-wk low
USD 31,82
Beta
0,68
Shares outstanding
130,80 m
No. of employees
5 k
News stories
From web sources and news partners
Profile
Cochlear is a medical device company that designs, manufactures, and supplies the Nucleus cochlear implant, the Hybrid electro-acoustic implant and the Baha bone conduction implant. Based in Sydney, Cochlear was formed in 1981 as a subsidiary of Nucleus with finance from the Australian government to commercialise the implants pioneered by Dr. Graeme Clark, although the company later became separate. As of 2022, the company holds 50% of the cochlear implant market, with more than 250,000 people receiving one of Cochlear's implants as of 2015. Cochlear was named Australia's most innovative company by the Intellectual Property Research Institute of Australia in 2002 and 2003, and one of the world's most innovative companies by Forbes in 2011. Wikipedia
About Cochlear Ord ADR
CEODig Howitt
Employees5,4 k
Founded1981
HeadquartersSydney, Nieu-Suid-Wallis, Australië
SectorMedical device
Previous reportsAll values in AUD
Loading Previous Earnings...
Revenue
Net income
All values in AUD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
583,60 m
583,60 m
590,20 m
590,20 m
Cost of goods sold
159,60 m
159,60 m
184,40 m
184,40 m
Cost of revenue
159,60 m
159,60 m
184,40 m
184,40 m
Research and development expenses
76,40 m
76,40 m
85,20 m
85,20 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
224,70 m
224,70 m
239,40 m
239,40 m
Operating expense
297,85 m
297,85 m
321,20 m
321,20 m
Total operating expenses
457,45 m
457,45 m
505,60 m
505,60 m
Operating income
126,15 m
126,15 m
84,60 m
84,60 m
Other non operating income
-
-
-
-
EBT including unusual items
106,55 m
106,55 m
400,00 k
400,00 k
EBT excluding unusual items
128,25 m
128,25 m
86,55 m
86,55 m
Income tax expense
25,80 m
25,80 m
7,50 m
7,50 m
Effective tax rate
24,21%
24,21%
1 875,00%
1 875,00%
Other operating expenses
-3,25 m
-3,25 m
-3,40 m
-3,40 m
Net income
80,75 m
80,75 m
-7,10 m
-7,10 m
Net profit margin
13,84%
13,84%
-1,20%
-1,20%
Earnings per share
-
-
-
-
Interest and investment income
4,20 m
4,20 m
900,00 k
900,00 k
Interest expense
-3,15 m
-3,15 m
-3,45 m
-3,45 m
Net interest expenses
1,05 m
1,05 m
-2,55 m
-2,55 m
Depreciation and amortization charges
-
-
-
-
EBITDA
151,95 m
151,95 m
88,00 m
88,00 m
Gain or loss from assets sale
-
-
5,80 m
5,80 m
AI content may include mistakes. Learn more
Google-programme